Use of nitric oxide synthase inhibitors for the treatment of inflammatory disease and pain

IDrugs

Volumn 4, Issue 7, 2001, Pages 795-803

  Cheshire, David R ^a  

^a Department of Medicinal Chemistry Astra ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001432877     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. Groves JT, Wang CCY: Nitric oxide synthase: models and mechanisms. CurrOpin Chem Biol (2000) 4(6):687-695.
2. Roerig S, Wolf R, Grisham MB: Nitric oxide, chronic joint inflammation, and pain. In: Nitric Oxide. Ignarro LJ (Ed), Academic Press (2000):873-894.
3. Luo ZD, Cizkova D: The role of nitric oxide in nociception. Curr Rev Pain (2000) 4(6):459-466.
4. Creamer P: Osteoarthritis pain and its treatment. Curr Opin Pheumatol (2000) 12(5):450-455.
5. Pelletier JP, Lascau-Coman V, Jovanovic D, Fernandas JC, Manning P, Connor JR, Currie MG, Martel-Pelletier J: Selective inhibition of inducible nitric oxide synthase in experimental Osteoarthritis Is associated with reduction In tissue levels of catabolic factors. J
6. Rheumatol(\999) 26(9):2002-2014. Evidence for the involvement ofiNOS in an experimental model of OA.
7. Tepperman BL, Whittle BJR: Physiological and pathophysiological roles of nitric oxide in gastrointestinal function. In: Mme Oxide. Ignarro LJ (Ed), Academic Press (2000):725-731.
8. Tepperman BL, Whittle BJR: Therapeutic implications of the nitric oxide pathway in gastrointestinal diseases. Drug De v (2000) :21-60.
9. Ashina M, Lassen, LH, Bendtsen L, Jensen R and Diesen J: Effect of inhibition of nitric oxide synthase on chronic tension-type headache: a randomized crossover trial. Lancet (1999) 353(9149):287-289.
10. Olesen J, Jansen-Olesen I: Nitric oxide mechanisms in migraine. Pathol B/o/(2000) 48(7):648-657.
11. Wang Y, Newton DC, Robb GB, Kau CL, Miller TL, Cheung AH, Hall AV, VanDamme S, Wilcox JN, Marsden PA: RNA diversity has profound effects on the translation of neuronal nitric oxide synthase. Proc Natl Acad Sei USA (1999) 96(21):12150-12155.
12. Wang Y, Newton DC, Marsden PA: Neuronal NOS: gene structure, mRNA diversity, and functional relevance. Crit Rev Neurobiol (1999) 13(1):21-43.
13. Grasemann H, Yandava CN, Storm van's Gravesande K, Deykin A, Pillar! A, Ma J, Sonna LA, Lilly C, Stampfer UJ, Israel E, Silverman EK, Drazen JM: A neuronal NO synthase (NOS1) gene polymorphism is associated with asthma. Biochem Biophys Res Commun (2000) 272(2):391-394.
14. Gao PS, Kawada H, Kasamatsu T, Mao XQ, Roberts MH, Miyamoto Y, Yoshimura M, Saitoh Y, Yasue H, Nakao K, Adra CN, Kun JF, Moro-oka S, Inoko H, Ho LP, Shirakawa T, Hopkin JM: Variants of NOS1, NOS2, and NOS3 genes in asthmatics. Biochem Biophys Res Commun (2000)267(3):761-763.
15. Rutgers SR, van der Mark THW, Coers W, Moshage H, Timens W, Kauffman HF, Koeter GH and Postma DS: Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease. Thorax (1999) 54(7):576-580.
16. Bames PJ: Chronic obstructive pulmonary disease. New Engl J Med (2000) 343(4):269-280.
17. Graver R, Zaccardelli D, Couce G, Guntupalli K, Watson D, Vincent JL: An open-label dose escalation study of the nitric oxide synthase inhibitor, Af-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Crit Care Med(1999) 27:913-922.
18. Cobb JP: Use of nitric oxide synthase Inhibitors to treat septic shock: the light has changed from yellow to red. [editorial comment]. Crit Care Med (1999) 27:855-856.
19. Naka M, Nanbu T, Kobayashi K, Kamanaka Y, Komeno M, Yanase R, Fukutomi T, Fujimara S, Seo HG, Fujiwara N, Ohuchida S, Suzuki K, Kondo K, Taniguchi N: A potent inhibitor of inducible nitric oxide synthase, ONO-1714, a cyclic amidine derivative. Biochem Biophys Res Commun (2001) 270:663-667.
20. Hagman WK, Caldwell CG, Chen P, Durette PL, Esser CK, Lanza TJ, Kopka IE, Guthikonda R, Shah SK, Maccoss M, Chabin RM, Reicher D, Grant SK, Green BG, Humes JL, Kelly TM, Luell S, Meurer R, Moore V, Pacholok SG, Pavia T, Williams HR, Wong KK: Substituted 2aminopyridines as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett (2000) 10:1975-1978.
21. Gustafsson D, Nystrom JE, Cartsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann JK, Ungell AL, Sorensen H, Nagard S, Abrahamsson A, Bylund R: The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res (2001)101(3):171-181.
22. McMillan K, Adler M, Auld D: Allosteric inhibitors of Inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc Natl Acad Sei USA (2000) 97:1506-1511.
23. Young RJ, Beams RM, Carter K, Clark HA, Coe DM, Chambers CL, Davies PI, Dawson J, Drysdale MJ, Franzman KW, French C, Hodgson ST, Hodson HF, Kleanthous S, Rider P, Sanders D, Sawyer DA, Scott KJ, Shearer BG, Stocker R, Smith S, Tackley MC, Knowles RG: Inhibition of inducible nitric oxide synthase by acetamldine derivatives of hetero-substrtuted lysine and homolysine. Bioorg Med Chem Lett (2000) 10:597-600.
24. Beswick P, Alderton W, Beams R, Carter K, Chambers L, Coe D, Dawson J, Drysdale M, John M, Franzman K, French C, Hodgson S, Hudson H, Knowles R, Sanders D, Sawyer D, Young R: Highly selective amino-acid derived iNOS (NOS-2) Inhibitors. Acta Physiol Scand Suppl (1999):P197.
25. Löwe JA: In vivo characterization of a novel neuronal nitric oxide synthèse inhibitor. Nat Med Chem Symp (2000) 27(Kansas City):A-04.
26. Löwe JA 3rd: A new class of selective and potent inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett (1999) 9:2569-2572.
27. Hagen TJ, Bergmanis M, Kramer SW, Fok KF, Schmelzer AE, Pitzele BS, Swenton L, Jerome GM, Kommeier CM, Moore WM, Branson LF, Connor JR, Manning PT, Currie MG, Hallinan EA: 2-lminopyrrolidines as potent and selective inhibitors of human inducible nitric oxide synthase. J Med Chem (1998) 41(19):3675-3683.
28. Hansen DW, Peterson KB, Trivedi M, Webber RK, Tjoeng FS, Moore WM, Jerome GM, Kommeier CM, Manning PT, Connor JR, Misko TP, Currie, Mark G, Pitzele BS: 2-lminohomopiperidinium salts as selective inhibitors of inducible nitric oxide synthase (iNOS). J Med Chem(1998) 41(9):1361-1366.
29. Webber RK, Metz S, Moore WM, Connor JR, Currie MG, Fok KF, Hagen TJ, Hansen DWJ, Jerome GM, Manning PT, Pitzele BS, Toth MV, Trivedi M, Zupec ME, Tjoeng FS: Substituted 2-iminopiperidines as inhibitors of human nitric oxide synthase isoforms. J Med Chem (1998)41(1):96-101.
30. Löwe JA: Nitric oxide synthase inhibitors: recent patent activity. IDmgs (2000) 3(1):63-72. A review of the nitric oxide patent literature up to 1999.
31. Lee Y, Martasek P, Roman Ul, Silverman RB: 1H-Pyrazole-1carboxamidines: new inhibitors of nitric oxide synthase. Bioorg Med Chem Lett (2000) 10:2771-2774.
32. Shankaran K, Donneley KL, Shah SK, Caldwell CG, Chen P, Hagmann WK, Humes, John L, Pacholok SG, Grant SK and MacCoss M: Evaluation of (1,4)-2-lmino-oxazep!nes, thiazepines and diazepines as inhibitors of nitric oxide synthase (NOS) enzymes. ACS (2000) 220(Washington DC):MEDI 216.
33. Froelich LG, Kotsonis P, Traub H, Taghavi-Moghadam S, AI-Masoudi N, Hofmann H, Strobel H, Matter H, Pfleiderer W, Schmidt HHHW: Inhibition of neuronal nitric oxide synthase by 4-amino pteridine derivatives: structure-activity relationship of antagonists of (6R)5,6,7,8-tetrahydrobiopterin cofactor. J Med Chem (1999) 42(20):4108-4121.
34. Fischmann TO, Hruza A, Niu XD, Fossetta JD, Lunn CA, Dolphin E, Prongay AJ, Reichert P, Lundell DJ, Narula SK, Weber PC: Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nature Struct /o/(1999) 6(3):233-242.
35. Crane BR, Arvai AS. Gachhhui R, Wu C, Ghosh DK, Getzoff ED, Steuhr DJ, Tainer JA: The structure of nitric oxide synthase oxygenase domain and inhibitor complexes. Science (1997) 278(5337):425-431.
36. Crane BR, Arvai AS, Ghosh DK, Wu C, Getzoff ED, Stuehr DJ, Tainer JA: Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science (1998) 279(5359):2121-2126.
37. Li H, Raman CS, Glaser CB, Blasko E, Young TA, Parkinson JF, Whitlow M, Poulos TL: Crystal structures of zinc-free and -bound heme domain of human Inducible nitric-oxide synthase. Implications for dimer stability and comparison with endothelial nitric-oxide synthase. J Biol Chem (1999) 274(30):21276-21284.
38. MONSANTO COMPANY (Manning PT, Pelletier JP, Pelletier JM, Connor JR, Currie MG): Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors. WO-00013709 (2000).
39. ONO PHARMACEUTICAL Co LTD (Taniguchi N, Kobayashi K, Naka M): Preparation of condensed piperidine derivatives as nitrogen monoxide synthase inhibitors. EP-00870763 (1998).
40. ONO PHARMACEUTICAL Co LTD (Naka M, Kobayashi K): Analgesics. WO00074678 (2000).
41. ONO PHARMACEUTICAL Co LTD (Taniguchi N, Suzuki K): Condensed piperidine derivatives for treatment of Inflammatory ophthalmic, disease. JP-99145348 (1999).
42. ONO PHARMACEUTICAL Co LTD (Taniguchi N, Suzuki K): Therapeutic agent for uveitis.JP-2000319181 (2000).
43. ASTRA AB (Hamley P, Tinker A): A pharmaceutical combination comprising a COX-2 inhibitor and a iNOS inhibitor. WO-00000200 (2000).
44. ASTRA PHARMACEUTICALS LTD (Hamley P, Tinker A): Novel combination. WO-09918960(1999).
45. ASTRA PHARMACEUTICALS LTD (Hamley P, Tinker A): Compounds. WO00006576 (2000).
46. ASTRA PHARMACEUTICALS LTD (Hamley P, Pimm A, Tinker A): Compounds. WO;09901455 (1999).
47. ASTRA PHARMACEUTICALS LTD (Hamley P, Richard J, Pimm A, Tinker A, Beaton H, Mcinally T): Pharmaceutically active quinazoline compounds. WO-09714686 (1997).
48. ASTRA PHARMACEUTICALS LTD (Mcinally T, Tinker A): Compounds. WO09845294(1998).
49. ASTRA PHARMACEUTICALS LTD (Mcinally T, Tinker A, Hamley P): Compounds. WO-09846611 (1998).
50. ASTRAZENECA PLC (Matz J, McDonald J, Wu E): New tricyclic amidine derivatives as inhibitors of nitric oxide synthase. WO-00073313 (2000).
51. ASTRAZENECA PLC (Matz J, McDonald J, Wu E): Compounds. WO00073312 (2000).
52. ASTRA AB (Macdonald J, Matz J, Shakespeare W): Amidine derivatives as Inhibitors of nitric oxide synthase. WO-09850382 (1998).
53. ASTRA AB (Macdonald J, Matz J, Shakespeare W): Compounds. WO09850380 (1998).
54. ASTRAZENECA PLC (Cheshire D, Connolly S, Cox D, Hamley P, Luker T, Mete A, Pimm A, Stocks M): 5,7-Bicyclic amidine derivatives useful as nitric oxide synthase inhibitors. WO-00064904 (2000).
55. ASTRAZENECA PLC (Cook A, Hamley P, Tinker A): Compounds. WO00027842 (2000).
56. ASTRAZENECA PLC (Connolly S, Cox D): Compounds. WO-00021934 (2000).
57. SCHERING AG (Jaroch S, Rehwinke H, Hölscher P, Sülzle D, Hillmann M, Burton GA, McDonald FM): 3,4-Dihydroquinoline derivatives äs nitrogen monoxide synthase (NOS) inhibitors. WO-09941240 (1999).
58. SCHERING AG (Jaroch S, Rehwinkel H, Hölscher P, Sülzle D, Hillmann M, Burton GA, McDonald FM): Fluorinated 3,4-dihydroquinoline derivatives used as NOS inhibitors. WO-00029381 (2000).
59. SCHERING AG (Jaroch S, Rehwinkel H, Hölscher P, Sülzle D, Hillmann M, Burton GA, McDonald FM): Aminoalkyl-3,4-dihydroquinoline derivatives äs NO-synthase Inhibitors. WO-00017167 (2000).
60. SCHERING AG (Jaroch S, Rehwinkel H, Hölscher P, Sülzle D, Hillmann M, Burton GA, McDonald FM): Benzoxazine and benzothiazine derivatives and their use in medicines. WO-00017173 (2000).
61. SCHERING AG (Hölscher P, Rehwinkel H, Jaroch S, Sülzle D): Benzoxazine and benzothiazine derivatives and their use in pharmaceutlcals. WO-09912915 (1999).
62. SCHERING AG (Burton G, Davey DD, Hillmann M, Hölscher P, Pribilla l, Rehwinkel H, Sülzle D): Substituted heterocycles and their use In medicaments. WO-09850372 (1998).
63. SCHERING AG (Hölscher P, Rehwinkel H, Jaroch S, Sülzle D, Hillmann M, Burton GA, McDonald FM): Benzoxazine and benzothiazine derivatives and the use thereof In medicaments. VVO-00114347 (2001).
64. SCHERING AG (Burton G A, Hillmann M, Hölscher P, Jaroch S, Mcdonald FM, Rehwinkel H, Sülzle D): Thienooxazines äs NOS-inhibitors. WO00024746 (2000).
65. BERLEX LABORATORIES INC/PHARMACOPOEIA INC (Amaiz DO, Baldwin JJ, Davey DD, Devlin JJ, Dolle RE, Erickson SD, Mcmillan K, Morrissey MM, Ohlmeyer MHJ, Pan G, Paradkar VM, Parkinson J, Phillips GB, Ye B, Zhao Z): W-Heterocyclic derivatives as NOS Inhibitors. WO00114371 (2001).
66. BERLEX UBORATORIES INC/PHARMACOPOEIA INC (Amaiz DO, Baldwin JJ, Davey DD, Devlin JJ, Dolle RE, Erickson SD, McMillan K, Morrissey MM, Ohlmeyer MHJ, Pan G, Paradkar VM, Parkinson, JP, Gary B, Ye B, Zhao Z et at): W-Heterocyclic derivatives as NOS inhibitors. WO09837079(1998).
67. FUJISAWA PHARM Co LTD (Ohkawa T, Ohne K, Oku T, Setoi H, Shima I, Yoshihara K, Zenko T): Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production. WO-09957114 (1999).
68. FUJISAWA PHARM Co LTD (Itoh Y, Yatabe T, Inoue T, Hamashima H): New indolyt and benzofuranyl carboxamides as inhibitors of nitric oxide production. WO-09745425 (1997).
69. FUJISAWA PHARM Co LTD (Shima I, Ohkawa T, Ohne K, Zenkoh T, Sato K): W-lmidazolylmethyl carboxamides as nitric oxide production inhibitors. WO-00102387 (2001).
70. FUJISAWA PHARM Co LTD (Sakai F, Yamazaki H, Chida N, Nakayama O, Yokota Y): New use. WO-09951215 (1999).
71. FUJISAWA PHARM Co LTD (Take K, Tomishima M): Pyridine compounds and their pharmaceutical use. WO-00049015 (2000).
72. GLAXO GROUP LTD (Beswick PJ, Kleanthous S, Young RJ): Nitric oxide synthase inhibitors. WO-9962875 (1999).
73. THE WELLCOME FOUNDATION LTD (Beams RM, Hodson HF, Palmer RMJ): Amidino derivatives and their use as nitric oxide synthase inhibitors. WO-09313055 (1993).
74. THE WELLCOME FOUNDATION LTD (Hodson HF, Palmer RMJ, Sawyer DA, Knowles RG, Franzmann KW, Drysdale MJ, Smith S, Davies PI, Clark HAR, Shearer BG): Enzyme inhibitors. WO-09534534 (1995).
75. ONO PHARM Co LTD (Tamiguchi N, Kobayashi K, Kusuda S): Nitric oxide synthase inhibitors. JP-10120654 (1998).
76. ONO PHARM Co LTD (Tanikuchi N, Kobayashi K, Kusuda S): Nitric oxide synthase inhibitors. JP-10036351 (1998).
77. ONO PHARM Co LTD (Taniguchi N, Kobayashi K, Fujii A): Nitric oxide synthase inhibitors. JP-10265461 (1998).
78. ONO PHARM Co LTD (Taniguchi N, Kobayashi K, Hisakazu K): Nitric oxide synthase inhibitors. JP-10001470 (1998).
79. PFIZER (Löwe JA): 2-Aminopyridines containing fused ring substituents. WO-00050400 (2000).
80. PFIZER (Löwe JA): 2-Aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors. WO-09962883 (1999).
81. PFIZER (Löwe JA): Branched alkoxy-substituted 2-aminopyridines as NOS inhibitors. WO-09911620 (1999).
82. PFIZER (Löwe JA): 2-Aminopyridines containing fused ring substituents as NOS inhibitors. WO-09910339 (1999).
83. PHARMACIA CORP (Awasthi AK, Hagen TJ, Hallinan EA, Hansen DW, Massa MA, Metz S, Moore WM, Moormann AE, Pitzele BS, Schölten JA, Sikorski JA, Snyder JS, Toth MV. Wang L, Webber RK, Yuan C): Heterobicyclic and tricyclic nitric oxide synthase inhibitors. WO09964426 (1999).
84. PHARMACIA CORP (Hansen DW, Currie MG, Hallinan EA, Fok KF, Hagen TJ, Bergmanis AA, Kramer SW, Lee LF, Metz S, Moore WM, Peterson KB, Pitzele BS, Spangler DP, Webber RK, Toth MV, Trivedi M, Tjoeng FS): Amidino derivatives useful as nitric oxide synthase inhibitors. US-06046211 (2000).
85. PHARMACIA CORP (Bergmanis AA, Gapud RE, Hagen TJ, Hallinan EA, Hansen DW, Kramer SW, Metz S, Peterson KB, Pitzele BS, Tjoeng FS, Toth MV, Trivedi M, Tsymbalov S, Webber RK, Toth M): 1,3-Diazaheterocycles and their use as nitric oxide synthase inhibitors. WO09905131 (1999).
86. PHARMACIA Copp (Hagen TJ, Hallinan EA, Hansen DW, Pitzele BS, Rueppel ML, Webber RK): Novel heterocyclic amino carbonyl derivatives useful as nitric oxide synthase inhibitors. WO-00063195 (2000).
87. PHARMACIA CORP (Gapud RE, Hagen TJ, Hallinan EA, Hansen DW, Pitzele BS, Metz SS, Webber RK, Tjoeng FS, Manning RE, Toth MV): Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors. US-06207708 (2001).
88. PHARMACIA CORP (Gapud RE, Hagen TJ, Hallinan AE, Hansen DW, Manning RE, Metz S, Pitzele BS, Tjoeng FS, Toth MV, Webber RK): Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors. US-05981511 (1999).
89. PHARMACIA CORP (Hagen TJ, Hallinan EA, Hansen DW, Rueppel ML, Webber RK): Novel hydroxamidino carboxylate derivatives useful as nitric oxide synthase Inhibitors. WO-00044731 (2000).
90. PHARMACIA CORP (Hagen TJ, Hallinan EA, Hansen DW, Pitzele BS, Rueppel ML, Webber RK): Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors. WO-00026195 (2000).
91. PHARMACIA CORP (Hallinan EA, Hansen DW, Tsymbalov S): Aminotetrazole derivatives useful as nitric oxide synthase inhibitors. WO-09615120 (1996).
92. PHARMACIA CORP (Hallinan EA, Pitzel BS, Spangler DP, Bergmanis AA, Hagen TJ, Tsymbalov S, Toth MV, Webber RK, Hansen DW, Awasthi AK): Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors. WO-09946240 (1999).
93. CHUGAI PHARMACEUTICAL COMPANY LTD (Makino T): Heterocyclic compounds having NOS inhibitory activities. WO-09923069 (1999).
94. CHUGAI PHARMACEUTICAL COMPANY LTD (Emura T, Kimura N, Nagafuji T): Substituted benzenes having NOS inhibitory effects. WO-09746515 (1997).
95. CHUGAI PHARMACEUTICAL COMPANY LTD (Esaki T, Makino T, Nagafuji T, Nishimura Y): Aromatic amine derivatives having NOS inhibitory effect. WO-09828257 (1998).
96. FISONS CORP (Gentile RJ, Murray, Robert JM, James E, Shakespeare W): Amidine derivatives with nitric oxide synthetase activities. WO09505363 (1995).
97. DAINIPPON PHARM Co LTD (Kobayashi N, Higuchi T, Hirobe Y, Nagano T): Selective inhibitors of nitric oxide synthase. JP-10237097 (1998).